The Study
12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment
This study looked at 16 older adults who lost weight—with or without a special medicine. It found that those who took the medicine lost more fat, but didn't lose more muscle than the others. But because it was so small and everyone knew who got the medicine, we can't be sure the medicine caused it—it might just be luck or other differences.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested if a diabetes/weight-loss drug called semaglutide helps older, obese people lose more fat and keep more muscle when combined with diet and exercise.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 562 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Even though both groups lost muscle, the drug group lost much more fat, so their body became leaner and healthier overall — like losing belly fat without losing as much arm or leg muscle.
- 2People who took semaglutide lost 8.1 kg total weight — 5.6 kg fat and 1.6 kg muscle — while those who didn’t took the drug lost 2.8 kg total — 1.5 kg fat and 0.9 kg muscle.
- 3Muscle loss was not significantly different between groups.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of the Endocrine Society
Year
2024
Authors
H. Ghanim, Ajay Chaudhuri, J. Hejna, Paresh Dandona
Related Content
Claims (7)
People taking GLP-1 receptor agonists for weight loss lose muscle mass in addition to fat mass.
Among elderly adults with obesity, taking semaglutide along with diet and exercise for 16 weeks leads to 2.9 kilograms more weight loss and a 0.08 improvement in fat-to-lean mass ratio compared to diet and exercise alone.
In elderly obese adults, taking semaglutide along with diet and exercise for 16 weeks leads to more total weight loss than diet and exercise alone, but the amount of lean mass lost is not significantly different between the two groups.
Among older adults with obesity, taking a weekly dose of semaglutide along with diet and exercise for 16 weeks leads to 5.6 kg more fat loss and 0.7 kg more lean mass loss than diet and exercise alone, improving the ratio of fat to lean mass without significantly changing total lean mass.
In elderly adults with obesity, taking semaglutide along with diet and exercise for 16 weeks leads to mild to moderate stomach side effects but does not cause low blood sugar or serious health problems.
In elderly adults with obesity, taking semaglutide along with diet and exercise for 16 weeks results in a measurable improvement in body composition, with a 0.08 unit increase in the fat-to-lean mass ratio.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.